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Abstract: The application of high-sensitivity cardiac troponins in clinical practice has led to an
increase in the recognition of elevated concentrations in patients without myocardial ischaemia. The
Fourth Universal Definition of Myocardial Infarction encourages clinicians to classify such patients
as having an acute or chronic myocardial injury based on the presence or absence of a rise or a
fall in cardiac troponin concentrations. Both conditions may be caused by a variety of cardiac and
non-cardiac conditions, and evidence suggests that clinical outcomes are worse than patients with
myocardial infarction due to atherosclerotic plaque rupture, with as few as one-third of patients
alive at 5 years. Major adverse cardiovascular events are comparable between populations, and
up to three-fold higher than healthy individuals. Despite this, no evidence-based strategies exist
to guide clinicians in the investigation of non-ischaemic myocardial injury. This review explores
the aetiology of myocardial injury and proposes a simple framework to guide clinicians in early
assessment to identify those who may benefit from further investigation and treatment for those with
cardiovascular disease.
Keywords: myocardial injury; myocardial infarction; universal definition
1. Introduction
The Fourth Universal Definition of Myocardial Infarction (UDMI) is an international
expert consensus document which aims to promote a better understanding of the aetiol-
ogy of myocardial injury and infarction, and to encourage a systematic approach to the
subsequent investigation, treatment and clinical outcomes. This new definition challenges
physicians to always consider the mechanisms of injury to ensure accurate diagnosis and
treatment.
2. Classification of Myocardial Injury and Infarction
Myocardial injury is an umbrella term which describes an elevation in cardiac troponin
concentration with at least one value above the 99th percentile upper reference limit (URL).
This term can be applied irrespective of aetiology and can be classified into acute or chronic
myocardial injury on the basis of a dynamic change in cardiac troponin concentration.
Typically, a relative change in troponin concentration of 20% is used [1].
The diagnosis of myocardial infarction is applied when acute myocardial injury occurs
in a patient with symptoms or signs of myocardial ischaemia on the electrocardiogram (ECG),
or new imaging evidence of a regional wall motion abnormality in a coronary territory.
Myocardial infarction is further stratified into five main subtypes (Figure 1) [1,2]. Type 1
myocardial infarction is due to atherosclerotic plaque rupture, leading to turbulent blood flow,
platelet aggregation and coronary artery occlusion, with subsequent myocardial ischaemia and
infarction. This phenotype is well understood, with evidence-based guidelines to inform both
primary and secondary prevention which has been shown to improve clinical outcomes [3].
Type 2 myocardial infarction is due to oxygen supply and demand imbalance in the absence of
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atherosclerotic plaque rupture. Typically, this occurs in the context of a physiological stressor
such as tachyarrhythmia, hypoxia, or hypotension. Clinical outcomes are significantly worse
than type 1 myocardial infarction. This can be explained in part by the age and co-morbidities
of the patients affected, but also may reflect suboptimal treatment of underlying coronary
and structural heart disease [4–6]. Type 3 myocardial infarction occurs in the setting of
sudden death prior to biomarker sampling. Type 4 myocardial infarction events occur due
to percutaneous coronary intervention (4a) or as a result of stent thrombosis (4b) or in-stent
restenosis (4c). Type 5 myocardial infarction occurs after cardiac surgery.
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Figure 1. Sub-types of myocardial injury and infarction as per the Fourth Universal Definition of
Myocardial Infarction.
3. Detecting Myocardial Injury in Clinical Practice
The clinical application of cardiac biomarkers for the diagnosis of myocardial in-
farction has evolved from the use of non-specific indicators of muscle ischaemia and
breakdown, including creatine kinase myocardial band (CK-MB), myoglobin, lactate dehy-
drogenase (LDH) and aspartate aminotransferase (AST), to the use of cardiac troponin as
the only recommended biomarker [3,7]. Cardiac troponin exists as a complex in a series of
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proteins that form the thin filament in muscle. Troponin binds with calcium which allows
bonding of actin and myosin, responsible for skeletal and cardiac muscle contraction [8].
The identification of cardiac-specific troponin I and T isoforms facilitated the development
of biochemical assays which are highly sensitive and specific for cardiomyocyte injury.
Both subtypes are released into the bloodstream in response to injury, but are not specific
to an ischaemic aetiology [9,10].
Cardiac myocytes may release troponin into the blood plasma through a variety of
mechanisms beyond cell necrosis and membrane rupture [11], but the pathophysiology
is poorly understood, with most evidence existing in vitro. Non-ischaemic mechanisms
may occur indolently and explain the silent release of troponin in patients with chronic
myocardial injury. Reported mechanisms include normal cardiac cellular turnover, apop-
tosis [12] and free bound cytoplasmic troponin release through membranous blebs [13]
(Figure 2). To test whether transient ischaemia affects troponin concentration in practice,
a recent study measured blood high-sensitivity cardiac troponin (hs-cTn) concentration
after balloon inflation within the left anterior descending coronary artery in a population
of patients with otherwise angiographically normal coronary arteries. Troponin elevation
was observed in all three high-sensitivity troponin assays just fifteen minutes after balloon
occlusion for only 30 s, and this was elevated above the 99th percentile in 25% of patients
sampled with hs-cTn T, fulfilling the biochemical criteria or myocardial infarction [14].
This demonstrates the remarkable sensitivity of these assays, which are able to detect
myocardial injury in the context of transient myocardial ischaemia without infarction.
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Cardiac troponin assays have evolved from contemporary sensitive to the hs-cTn
immunoassays widely utilised today [7]. These assays can detect troponin isoforms I and T
in the majority of healthy individuals, with some able to measure concentrations in over
90% [15,16]. A number of assays are commercially available, with a recent global survey of
1902 medical centres across 23 countries, highlighting that 96% used cardiac troponin as
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the primary diagnostic biomarker for myocardial infarction [17]. It is important to note
that each assay has its own performance characteristics and reference ranges which are not
transferrable. Clinicians must be aware of the assay in use at their own centre. A recent
study evaluated 12 of the most commonly used assays in an ethnically diverse universal
sample bank of healthy patients. The authors aimed to define sex-specific 99th percentiles
using each assay, and found that only 8 assays were able to measure cardiac troponin in
more than 50% of healthy men and women, thus fulfilling the criteria to be defined as a
true high-sensitivity assay [18]. The magnitude and change in troponin concentration over
time may serve as a useful tool for identifying the underlying mechanism of myocardial
damage with several studies revealing peak troponin to be significantly higher in type 1
myocardial infarction than type 2 myocardial infarction and myocardial injury [19,20].
4. Epidemiology of Acute and Chronic Myocardial Injury
Troponin elevation is common in conditions other than acute coronary syndromes. A
number of studies in both selected and unselected populations suggest that non-ischaemic
myocardial injury is the most common cause of elevation in cardiac troponin concen-
tration, [9,16–19], with more recent studies discriminating between acute and chronic
myocardial injury [21–24] (Table 1). In an observational cohort study of 22,589 patients
who had hs-cTnT measured in a single emergency department (ED) in Sweden [22,23], 65%
of those with elevated cardiac troponin concentrations had myocardial injury (30% acute
and 35% chronic), with the remaining 35% having a diagnosis of myocardial infarction.
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The High-Sensitivity Troponin in the Evaluation of Patients with Suspected Acute
Coronary Syndrome (High-STEACS) trial evaluated 48,282 consecutive patients with
suspected acute coronary syndrome tested using a hs-cTnI assay and demonstrated that of
the 9115 patients with elevated cardiac troponin concentrations, 33% had non-ischaemic
myocardial injury (18% acute and 12% chronic), with the remaining 67% having a diagnosis
of myocardial infarction (50% type 1 and 17% type 2 myocardial infarction). In a further
study of unselected consecutive patients who attended the emergency department (ED)
and underwent blood testing on clinical indication, hs-cTnI measurements were conducted
in all patients as a suppressed test. This found elevated cardiac troponin concentrations in
13.7% (114/1054), of which 96% were due to non-ischaemic myocardial injury [21,31].
In an observational cohort study of 1640 consecutive unselected patients in which
troponin sampling was performed on clinical indication in the ED, 56% of the 497 patients
with elevated troponin concentrations had non-ischaemic myocardial injury [25]. The wide
variation in incidence of myocardial injury could be explained by the difference in patient
selection for testing, study inclusion criteria and diagnostic adjudication with a higher
incidence of non-ischaemic myocardial injury seen in unselected patient cohorts.
5. Mechanisms of Myocardial Injury
5.1. Acute Myocardial Injury: Cardiac Mechanisms
It is now widely recognised that a plethora of cardiac and non-cardiac conditions may
be responsible for both acute and chronic myocardial injury (Figure 3). Cardiac causes are
common with tachyarrhythmia the most frequently observed cause of acute myocardial
injury in clinical practice. Another common cause is acute decompensated heart failure,
where elevated troponin levels associated with worse outcomes [32]. Myocardial injury is
frequently observed following the direct insult of cardiac surgery [33], cardiac trauma or
contusions as a consequence of cardiopulmonary resuscitation [34]. Myopericarditis [35,36]
and less commonly endocarditis are associated with acute myocardial injury with the
mechanism for the latter thought to be due to associated left ventricular dysfunction. This
was suggested in a study of 97 patients with endocarditis and biomarker sampling at 1 and
7 days. Concentrations were higher in those with heart failure and valvular dysfunction.
This study also revealed BNP as well as troponin concentration to be good predictors of
mortality [37].
Takotsubo or stress cardiomyopathy is a poorly understood condition thought to be
caused by catecholamine induced coronary vasospasm. Despite this presumed ischaemic
aetiology, it is not considered a cause of myocardial infarction. Characteristically, there is
ballooning of the apical segment of the heart. These patients, however, quite often only
display a modest rise in troponin level in comparison to the degree of left ventricular
dysfunction and studies have suggested patients with high troponin levels at presentation
are unlikely to have Takotsubo cardiomyopathy [38,39]. Comparatively in myocarditis,
troponin elevation may be more marked and persistently elevated [40]. Although troponin
elevations have been demonstrated to have good discrimination for the diagnosis of my-
ocarditis and are recommended by expert consensus, the best diagnostic tool is cardiac
magnetic resonance imaging (cMRI) for those without complications such as cardiogenic
shock or acute heart failure, or endomyocardial biopsy for those patients with decompen-
sation where cMRI is not feasible or there is a high degree of diagnostic uncertainty [40].
Acute aortic syndromes including dissection can cause myocardial injury due left ventricu-
lar overload, coronary dissection, or in some cases a dissection flap causing coronary artery
ostial disruption which may present with ST-segment elevation [41].
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5.2. Acute Myocardial Injury: Non-Ca diac Mechanisms
Non-cardiac causes of acute myocardial injury include pulmonary embolism (PE),
with myocardial injury occurring due to hypoxia [35,42], or haemodynamic effects result-
ing in right heart strain. The European Society of Cardiology (ESC) guidelines identify
tropo in as a prognostic marker in atie ts it PE to help identify those at high risk of
death and consideration of thrombolysis t erapy [43,44]. There are neurological causes of
myocardi l i jury including stro [45] and sub-arachnoid haemorrhage [46]. The exact
mecha ism of troponin elevation has not been characterised. However, the accompanied
hypertension, cat holami e releas and vasoco triction in these cond tions are likely to
be contributary with dynamic ECG changes of en seen. Hypertension h been further
demonstrated to be linked to myocardial injury in a sec ndary analysis of 5251 patients in
the Atherosclerosis Risk in Communities Study (ARIC), with isolated systolic blood pres-
sure positively correlating with cardiac troponin concentration [47]. The secondary effects
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of sepsis have been shown to lead to myocardial injury [48,49], with the profound haemo-
dynamic consequences of severe infection implicated in addition to direct myocardial
injury [35].
Other systemic stressors such as non-cardiac surgery [50] have been associated
with acute myocardial injury and have been associated with post procedural mortality.
Chemotherapeutic agents such as anthracyclines and Herceptin can cause left ventricular
dysfunction and associated myocardial injury. Cardiac biomarkers are often monitored
in conjunction with echocardiography to facilitate early identification prior to established
cardiac toxicity [51].
Myocardial injury has also been documented as a transient phenomenon after high-
intensity exercise [52,53]. Troponin concentrations are higher after short intense periods
of exercise than following prolonged exercise at lower intensity, and in healthy persons
levels return to pre-exercise levels within 24 h. Elevation in both troponin I and T has
been documented in athletes and non-athletes after major endurance events, with up to
43% of non-athletes having concentrations above the 99th percentile [54–56]. Historically,
rhabdomyolysis, which can occur after intense exercise or muscle injury, has been posi-
tively correlated with elevated cardiac troponins [57]. However, a recent adjusted analysis
revealed high levels of skeletal muscle breakdown not to be a relevant non-cardiac cause
of acute myocardial injury [58]. Aengevaeren and colleagues evaluated 12 moderately to
highly trained athletes shortly after participating in a marathon, of whom 7 (64%) had ele-
vation in cardiac troponin I above the 99th percentile. They utilised advanced multi-modal
cMRI and observed increased mean diffusivity and fractional anisotropy of myocardial
tissue water from baseline which was correlated to troponin concentration. An increase in
mean extracellular volume in cardiomyocytes of all athletes was also demonstrated. This
study supports the theory of reversible myocardial injury through increased cardiomyocyte
permeability [59]. A further study measured high-sensitivity troponin I in 725 people
after 30–55 km of walking. They observed an increase in prevalence of participants with
troponin concentrations over the 99th percentile from 1 to 9% after walking. During an
average of 43 [23–77] months of follow up, patients with acute myocardial injury had a
significantly increased risk of all-cause mortality or major adverse cardiovascular events
(MACE) after adjustment for age, sex and cardiovascular risk factors (adjusted hazard ratio
(aHR) 2.48; 95% Confidence Interval (CI) 1.29 to 4.78). Whilst this association may be due
to unmeasured confounding or the presence of unrecognised cardiovascular disease, they
suggest that troponin release during exercise may not always be a benign response [60].
5.3. Chronic Myocardial Injury: Cardiac Mechanisms
Chronic myocardial injury tends to reflect a steady disease state, and is frequently
observed in chronic heart failure [61]. A meta-analysis of patients with elevated baseline
cardiac troponin in chronic stable heart failure demonstrated an association with all-cause
mortality (hazard ratio (HR) 2.85; 95% CI 2.02 to 4.03) and a higher rate of adverse cardio-
vascular outcomes (HR 2.38; 95% CI 1.63 to 3.49) when compared to similar populations in
which there was little evidence of myocardial injury [62]. Other cardiac causes of chronic
injury include cardiomyopathies [63,64] including infiltrative cardiomyopathies such as
sarcoidosis, [65] haemochromatosis, amyloidosis [66] and hypertensive heart disease [67].
Valvular heart disease is also commonly associated with elevation in cardiac troponin
concentration. The Early Valve Replacement Guided by Biomarkers of LV Decompensation in
Asymptomatic Patients with Severe AS (EVoLVeD) (NCT:03094143) is a randomised controlled
trial in patients with asymptomatic severe aortic stenosis aiming to optimise the timing of
valvular surgery. In this trial, cardiac troponin is used as a screening marker of early cardiac
fibrosis to identify patients for cardiac magnetic resonance imaging. Patients with evidence of
mid-wall fibrosis are randomised to early valve replacement or watchful waiting.
The mechanisms responsible for chronic myocardial injury in patients with severe
or diffuse coronary artery disease are poorly understood. The Dual Antiplatelet Therapy
to Reduce Myocardial Injury (DIAMOND); (NCT:02110303) trial identified a cohort of
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patients with high-risk coronary plaque using coronary 18F-fluoride positron emission
tomography/coronary computed tomography. In the subset of patients with elevated
hs-cTn I concentrations ≥5 ng the addition of ticagrelor compared to placebo to standard
preventative therapy did not reduce cardiac troponin levels over one year. This implies
that subclinical plaque instability leading to ongoing micro-thrombosis is not the primary
contributing cause of measurable troponin concentrations in these patients [68].
The West of Scotland Coronary Prevention Study (WOSCOPS) trial randomised a
population of 6595 men with moderate hypercholesterolaemia to a placebo or pravastatin 40
mg. In a secondary analysis of this trial, troponin concentrations were predictive of coronary
events and were modified by statin therapy, with the change in LDL at 1 year associated
with future coronary risk independent of cholesterol lowering. Furthermore, those with
decreasing troponin concentration by more than one-quarter, rather than increasing by
more than one-quarter, had a five-fold lower rate of future coronary events in both the
placebo group (HR 0.29; 95% CI 0.12 to 0.72 versus HR 1.95; 95% CI 1.09 to 3.49; p < 0.001
for trend) and the pravastatin group (HR 0.23; 95% CI 0.10 to 0.53 versus HR 1.08; 95% CI
0.53 to 2.21; p < 0.001 for trend). This suggests there may be value of repeated sampling in
patients with chronic troponin elevation to target those at high risk of future events and
monitor response to treatment [69].
5.4. Chronic Myocardial Injury: Non-Cardiac Mechanisms
Non-cardiac aetiologies of chronic myocardial injury include pulmonary hypertension,
toxins and diabetes mellitus [4,70]. However, probably the most frequently observed non-
cardiac cause of chronically elevated cardiac troponin levels is in patients with chronic renal
disease. Cardiovascular disease is common in patients with chronic kidney disease, with
half of all deaths in end-stage renal failure due to cardiovascular events [71]. However, the
aetiology of troponin elevation is unclear and may reflect either decreased renal clearance
or increased myocardial release of troponin.
The mechanisms by which troponin is broken down and excreted in humans remains
to be fully understood and despite its importance, little research has been conducted
in vivo. As with most large proteins, it is hypothesised that the predominant process
is by scavenger receptor-mediated clearance [72]. This extra-renal clearance has been
demonstrated in vitro during high levels of circulating cardiac troponin using experimental
models of rats with and without renal function. Cardiac troponin T concentration still
reduced over time after intravenous infusion of cardiac extracts in rats without kidney
function. Increased clearance of cardiac troponin T was only seen when levels were low [73].
This can likely be explained by scavenger receptors having reduced affinity for troponin
at such low concentrations and smaller degradation products of troponin readily passing
through the glomerular membrane. A further study using radiolabelled cardiac troponin
in rats revealed uptake in both the kidneys and liver, with liver uptake inhibited through
inhibition of endocytosis, suggesting both renal and extra-renal systems of clearance [74].
These studies may explain the correlation between those with reduced renal function and
slightly elevated concentrations of circulating cardiac troponin. However, animal models
may not be reflective of human physiology.
The Chronic Renal Insufficiency Cohort Study (CRIC) enrolled 3664 patients with
chronic renal disease and performed cardiac biomarker testing in all. High-sensitivity
cardiac troponin T concentrations were found to be independently associated with all-cause
mortality (HR 1.62; 95% CI 1.48 to 1.78). A further analysis of this cohort modelled to
adjust for age, sex, presence of cardiovascular disease and cardiac risk factors revealed
increased risk of cardiovascular death (aHR 1.87; 95% CI 1.65 to 2.11). There may be merit
in using cardiac troponin concentration to stratify cardiovascular risk in those with chronic
renal failure, identifying those with high circulating cardiac troponin concentrations for
aggressive primary and secondary preventative therapies for cardiovascular disease.
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6. Clinical Outcomes in Patients with Myocardial Injury
6.1. Mortality Outcomes
Outcomes in patients with acute and chronic myocardial injury are poor, with up to
72% of patients dead at five years [5] (Figure 4). In nearly all studies that have classified
patients according to the Fourth Universal Definition of Myocardial Infarction, death from
any cause was higher in patients with myocardial injury compared to type one myocardial
infarction (Table 1). Outcomes are likely to be strongly influenced by the prognosis of the
underlying condition responsible for myocardial injury and these patients tend to be older,
with more cardiac and non-cardiac co-morbidities [19,21–24,70,71].
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displayed as total non-ischaemic myocardial injury, shape size is proportional to the number of study participants.
Sark sian and colleagu s ev luated a consecutive patient cohort i Denmark who
had troponin measured on clini l indication. They found that 29% (1089/3762) of all
patie ts had non-ischaemic myocardial injury. In this cohort, 59% (645/1089) of patients
with myocardial injury were dead at 3.2 years, which was significantly higher than those
with type 1 myocardial infarction (29%) but not type 2 myocardial i farction (63%). Patients
with myocardial injury were more likely to present with dyspnoea and w re ol er, and
there was a higher incid nce of h art failure with lower peak troponin con entr tions
compared to those with type 1 myocardial infarction.
Smilowitz et al. studied a similar cohort of patients with troponin concentration
measured on clinical indication. They found non-ischemic myocardial injury in 175/710
(25%) of patients with a mean age of 74.9. However, in this cohort no difference in all
cause death was observed between those with type 1, type 2 myocardial infarction and
myocardial injury (30%, 31%, and 30%, respectively) at a median of 1.8 years. Differences
J. Clin. Med. 2021, 10, 2331 12 of 17
in outcomes may perhaps be explained by selection, as this cohort was nearly all male,
with a much higher proportion of type two myocardial infarction and less myocardial
injury. This cohort had a higher incidence of previous heart failure in the type 1 group
and no difference in incidence of chronic kidney disease, diabetes and chronic obstructive
pulmonary disease between all groups. When evaluating outcome studies in patients with
myocardial injury attention to the baseline characteristics, underlying concomitant disease
profiles, treatment and diagnostic adjudication must be considered as these variables are
likely to differ between both research and clinical sites.
6.2. Cardiovascular Outcomes
Most studies demonstrate that cardiovascular death and recurrent myocardial infarc-
tion are more common in patients with type 1 myocardial infarction, but patients with both
acute and chronic myocardial injury have a substantially higher risk than those without
myocardial injury [21–23,75].
Sandoval et al. evaluated 1640 unselected patients presenting to the emergency
department using a contemporary sensitive cardiac troponin assay. They report a 19%
MACE rate at 180 days in the 280 patients with myocardial injury. Interestingly, the only
independent predictors for death in this group were congestive heart failure (HR 2.04,
95% CI 1.19 to 3.51) and peak cardiac troponin (HR 1.74, 95% CI 1.18 to 2.55) [25]. In the
High-STEACS study, the risk of subsequent cardiovascular death or myocardial infarction
in patients with acute myocardial injury and chronic myocardial injury was four-fold
higher than in those without myocardial injury (cause specific hazard ratios 4.38, 95% CI
3.80 to 5.05) and (3.88, 95% CI 3.31 to 4.55), respectively.
Given the increased incidence of future MACE in patients with acute and chronic my-
ocardial injury, further cardiac investigation may plausibly improve care in this population.
There may be an opportunity for treatment optimisation whilst in hospital or at the point
of discharge with the potential to modify outcomes in this group.
7. Investigation and Management Strategies for Acute Myocardial Injury
In the absence of formal guidelines, we propose a simple framework to guide clinicians
when interpreting troponin results in patients who do not have myocardial infarction
(Figure 5).
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The primary goal of the assessing clinician should be to determine the correct diagnosis
at the first consultation to guide subsequent investigation and treatment. After myocardial
injury has been diagnosed on serial cardiac troponin testing, it is important to revisit the
history and ensure there are no features consistent with myocardial ischaemia which could
indicate myocardial infarction. In practice, differentiating acute non-ischaemic myocardial
injury from type 2 myocardial infarction can be challenging. This often occurs as the
classification of myocardial ischaemia is subjective on the basis of the clinical history and
electrocardiogram. Difficulties in discriminating between acute myocardial injury and
type 2 myocardial infarction can be exacerbated by atypical presentation of symptoms and
non-specific ECG changes. Interestingly, patients with type 2 myocardial infarction and
objective myocardial ischaemia on the electrocardiogram have been shown to have worse
outcomes than those with only subjective ischaemic features [76]. Identification of regional
ischaemia is important as it implies there may be a coronary mechanism, which may have
important consequences for management.
A 12-lead electrocardiogram should be performed in all patients with myocardial in-
jury. This is not only useful for exclusion of ischaemia, but may also indicate abnormalities
suggestive of cardiomyopathy, brady/tachyarrhythmias or pulmonary hypertension and
embolism which should be further investigated with monitoring or imaging. Haematology
and biochemistry investigations should be considered including a full blood count, clotting
screen, liver function tests, inflammatory markers, estimated glomerular filtration rate
and electrolytes, with additional tests such as thyroid function and d-dimer considered if
appropriate.
Further investigations should be guided by the history. In the acute setting, pleuritic
pain may represent a multitude of pathologies and a plain chest radiograph may indicate
infection or a primary lung pathology. Other causes such as myopericarditis should be
considered by interrogating the electrocardiogram for ST segment or T-wave changes
across different coronary territories. When pain occurs concomitantly with tachycardia
and hypoxia then PE should be excluded, with risk stratification using the Geneva score,
d-dimer and a CT pulmonary angiogram considered. Central chest pain which radiates
through to the back may represent aortic dissection which is a surgical emergency and ECG-
gated CT imaging should be performed if this condition is suspected. Other cardiovascular
symptoms such as breathlessness, leg swelling, orthopnoea and reduced exercise tolerance
may indicate heart failure which may have a valvular, structural, or chronic ischaemic cause.
In this instance echocardiography should be considered. Palpitations and syncope may
represent arrythmias in which case rhythm monitoring should be commenced. Detailed
clinical examination is important as this may indicate signs of systematic illness or infection.
An accurate medication history for both prescribed and not prescribed drugs is also
essential as these may be causal for myocardial injury including previous chemotherapy
agents and use of illicit substances such as methamphetamine or cocaine.
When there is a <20% change in troponin concentration on serial sampling then
myocardial injury should be classified as chronic. Similar consideration of the underlying
mechanism of myocardial injury is important, particularly the exclusion of structural or
hypertensive heart disease, and treatment should be optimised such as the case in heart
failure or chronic kidney disease.
In instances where cardiac imaging does not identify a clear cause of myocardial injury
in otherwise healthy individuals, clinicians should always consider laboratory error and the
possibility of analytical false positive results. This may occur due to heterophilic antibodies
or interferents, which can occur in ~1 in 1000 patients. In addition to laboratory testing,
clinicians should consider measuring an alternative commercially available troponin assay
to determine if results are concordant. This is particularly relevant for future admissions to
avoid unnecessary investigation or treatment.
Patients with acute and chronic myocardial injury are heterogenous, and an individu-
alised management strategy is needed for each patient. Careful attention to the underlying
mechanism of injury is important as a given treatment pathway may be advantageous for
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one patient but cause harm to another. For example, consider an elderly patient with a
background of chronic kidney disease and known moderate aortic stenosis. They present
with breathlessness and have stable troponin concentrations above the 99th percentile.
Their last echocardiogram was within one month which demonstrated unchanged left
ventricular function and similar aortic valve velocities to six months prior. Further investi-
gation is unlikely to influence management and will increase the healthcare burden with no
clear benefit to the patient, although it would be important to review the echocardiogram
to ensure the assessment of severity is accurate as if severe, elevated cardiac troponin con-
centrations are independently associated with mid-wall fibrosis and may merit assessment
for early valve replacement as outcomes in this group are much worse [77]. On the other
hand, consider a 42-year-old patient who presents with symptoms of decreased exercise
tolerance and shortness of breath. Identification of stable cardiac troponin concentrations
above the 99th percentile is highly abnormal, and likely to be indicative of an undiagnosed
cardiac pathology. Further investigations including a chest radiograph, electrocardiogram
and transthoracic echocardiography are indicated to identify structural abnormalities and
assess left ventricular function.
8. Conclusions
The implementation of highly sensitive troponin testing in an aging population has
increased the prevalence of acute and chronic myocardial injury in practice. Myocardial
injury is associated with worse outcomes irrespective of the underlying mechanism. Defin-
ing the underlying cause of myocardial injury is important and may have therapeutic
implications that could change care and prognosis.
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